KR930012035A - Sustainable Compositions Containing Somatotropin - Google Patents

Sustainable Compositions Containing Somatotropin Download PDF

Info

Publication number
KR930012035A
KR930012035A KR1019910024288A KR910024288A KR930012035A KR 930012035 A KR930012035 A KR 930012035A KR 1019910024288 A KR1019910024288 A KR 1019910024288A KR 910024288 A KR910024288 A KR 910024288A KR 930012035 A KR930012035 A KR 930012035A
Authority
KR
South Korea
Prior art keywords
composition
somatotropin
prepared
hydroxy propyl
soluble polymer
Prior art date
Application number
KR1019910024288A
Other languages
Korean (ko)
Other versions
KR0143767B1 (en
Inventor
김남중
조흥수
이병건
Original Assignee
최근선
주식회사 럭 키
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 최근선, 주식회사 럭 키 filed Critical 최근선
Priority to KR1019910024288A priority Critical patent/KR0143767B1/en
Publication of KR930012035A publication Critical patent/KR930012035A/en
Application granted granted Critical
Publication of KR0143767B1 publication Critical patent/KR0143767B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH] (Somatotropin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Abstract

본 발명은 생체내 활성인 소마토트로핀을 1종 이상의 수용성 중합체를 사용하여 과립화시킨 후 제피과정을 거쳐 제조된, 생체내에서 소마토트로핀을 지속성으로 방출하는 이식투여 가능한 조성물을 제공한다.The present invention provides an implantable composition for sustainably releasing somatotropin in vivo, which is prepared by granulating the in vivo active somatotropin with at least one water-soluble polymer and then subjecting it to epidermis. .

Description

소마토트로핀을 함유하는 지속성 조성물Sustainable Compositions Containing Somatotropin

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음As this is a public information case, the full text was not included.

Claims (13)

생체내 활성인 소마토트로핀을 1종 이상의 수용성 중합체를 사용하여 과립화시킨 후 제피(coating) 과정을 거쳐 제조된, 이식 투여 가능한 소마토트로핀의 지속성 방출형 조성물.A sustained release composition of transplantable administrable somatotropin, prepared by granulating the in vivo active somatotropin with at least one water soluble polymer and then coating. 제1항에 있어서, 상기 소마토트로핀을 20중량% 이상 포함하도록 제조된 조성물.The composition of claim 1, wherein the composition comprises 20% by weight or more of somatotropin. 제1항에 있어서, 소마토트로핀이 포유 동물의 뇌하수체로부터 추출하여 농축시켜 제조된 것임을 특징으로하는 조성물.The composition of claim 1, wherein the somatotropin is prepared by extracting from the mammalian pituitary gland and concentrating. 제1항에 있어서. 소마토트로핀이 미생물에 의한 DNA 재조합 방법으로 제조된 것임을 특징으로 하는 조성물.The method of claim 1. Somatotropin is a composition characterized in that produced by the DNA recombination method by a microorganism. 제1항에 있어서, 소마토트로핀이 소의 소마토트로핀 또는 돼지 소마토트로핀임을 특징으로 하는 조성물.The composition of claim 1 wherein the somatotropin is bovine somatotropin or porcine somatotropin. 제1항에 있어서, 소마토트로핀이 엘-알파-포스파티딜 콜린과 혼합된 동물 성장 호르몬임을 특징으로 하는 조성물.The composition of claim 1, wherein the somatotropin is an animal growth hormone mixed with L-alpha-phosphatidyl choline. 제1항에 있어서, 수용성 중합체의 함량이 전체 조성물의 70내지 80중량%인 것을 특징으로 하는 조성물.The composition of claim 1 wherein the content of water soluble polymer is from 70 to 80% by weight of the total composition. 제1항 또는 제7항에 있어서, 수용성 중합체가 폴리에틸렌 글리콜임을 특징으로 하는 조성물.8. A composition according to claim 1 or 7, wherein the water soluble polymer is polyethylene glycol. 제8항에 있어서, 폴리에틸렌 글리콜의 분자량이 20,000내지 35,000임을 특징으로 하는 조성물.The composition of claim 8 wherein the polyethylene glycol has a molecular weight of 20,000 to 35,000. 제1항에 있어서, 제피 과정중의 제피 용액으로 하이드록시 프로필 셀룰로우스를 사용하여 제조된 조성물.The composition of claim 1 prepared using hydroxy propyl cellulose as the coating solution during the coating process. 제1항에 있어서, 제피 과정중의 제피용액으로 하이드록시 프로필 메틸 셀룰로오스를 사용하여 제조된 조성물.The composition of claim 1, wherein hydroxy propyl methyl cellulose is used as the coating solution during the coating process. 제10항 또는 제11항에 있어서, 하이드록시 프로필 셀룰로오스 또는 하이드록시 프로필 에틸 셀룰로오스를 5내지 10% 농도로 용매에 용해시켜 사용하여 제조된 조성물.The composition according to claim 10 or 11, wherein the composition is prepared by dissolving hydroxy propyl cellulose or hydroxy propyl ethyl cellulose in a solvent at a concentration of 5 to 10%. 제1항에 있어서, 정제(tablet) 또는 펠렛(pellet) 형태인 것을 특징으로 하는 조성물.The composition of claim 1, wherein the composition is in the form of a tablet or pellets. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019910024288A 1991-12-24 1991-12-24 Sustained releasing conposition comprising somatotropin KR0143767B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019910024288A KR0143767B1 (en) 1991-12-24 1991-12-24 Sustained releasing conposition comprising somatotropin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019910024288A KR0143767B1 (en) 1991-12-24 1991-12-24 Sustained releasing conposition comprising somatotropin

Publications (2)

Publication Number Publication Date
KR930012035A true KR930012035A (en) 1993-07-20
KR0143767B1 KR0143767B1 (en) 1998-07-15

Family

ID=19325953

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910024288A KR0143767B1 (en) 1991-12-24 1991-12-24 Sustained releasing conposition comprising somatotropin

Country Status (1)

Country Link
KR (1) KR0143767B1 (en)

Also Published As

Publication number Publication date
KR0143767B1 (en) 1998-07-15

Similar Documents

Publication Publication Date Title
ATE271380T1 (en) METHOD FOR PRODUCING POLYMER MICELLE COMPOSITIONS LOADED WITH ACTIVE INGREDIENTS
KR940703713A (en) VERFAHREN ZUR HERSTELLUNG VON MI-KROKAPSELN
KR860008776A (en) Implantable composition and preparation method thereof
IL127582A (en) Perfume concentrate and paraffin-based object containing it
EP0461630A3 (en) Production process of microspheres
Pelletier et al. An ultrastructural study of sites of granule extrusion in the anterior pituitary of the rat
Manzon et al. The Effects of Exogenous Thyroxine (T4) or Triiodothyronine (T3), in the Presence and Absence of Potassium Perchlorate, on the Incidence of Metamorphosis and on Serum T4and T3Concentrations in Larval Sea Lampreys (Petromyzon marinusL.)
KR890009385A (en) Encapsulating Antifungal Compositions
Karasek et al. Influence of gonadotropic hormones on the ultrastructure of rat pinealocytes
UA90253C2 (en) Non-tabletted, chewable, individually dosed administration forms
FI935051A0 (en) Lanoliners are used for the penetration and preparation of water and the preparation of such substances or other biologically active substances.
KR930012035A (en) Sustainable Compositions Containing Somatotropin
ES461613A1 (en) Collagen compositions having crosslinking agent incorporated therein and the method of preparing the same
Perera et al. Effect of anoxia, glucose and thioglycollate on anaphylactic and compound 48/80-induced histamine release in isolated rat mast cells
Schelin et al. An electron microscopic study of normal and neoplastic acidophil cells of the rat pituitary
DE69736985D1 (en) BIOLOGICAL ACTIVE COMPOSITION
ATE310500T1 (en) BIOLOGICALLY ACTIVE COMPOSITION
GB1344727A (en) Pharmaceutical preparations comprising chondroitin sulphates a and c
PT873134E (en) AQUOSA FORMULATION OF PROLONGED LIBERATION COMPREENDING FACTOR OF LIBERATION OF HORMONE OF BOVINE GROWTH
CA2460042A1 (en) Inhibition of antigen presentation with poorly catabolized polymers
NZ508074A (en) Biologically active compositions, and methods for their preparation, comprising a carrier matrix supersaturated with active agent
Kurosumi et al. Fine structural aspects on the fate of rat black thyroids induced by minocycline
EP0032825A2 (en) Stabilized solutions of dioctyl calcium sulfosuccinate in corn oil
Dasgupta et al. The activity in vitro of growth hormone in reducing the respiratory quotient of rat diaphragm
JPS57181694A (en) Cultivation of fibroblast

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20040324

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee